Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model

Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model

Bibliographic Details
Main Authors:	J.A. Silva-Gómez, H.C. Monroy-Ramírez, M. Galicia-Moreno, A. Santos-García, J. Armendáriz-Borunda
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268120301009

Similar Items

Analysis of the molecular interaction of pirfenidone with PPAR-gamma and effects on the beta-catenine pathway in HEPG2 line
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Pirfenidone induces epigenetic changes modulating the activity of the ppargamma-SIRT1-DNMT1 axis in hepatic stellate cells
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model
by: J. Gutiérrez-Cuevas, et al.
Published: (2020-09-01)

Prolonged-release pirfenidone decreases hepatic miRNAs expression in a NAFLD/NASH experimental model
by: R. Escutia-Gutiérrez, et al.
Published: (2020-09-01)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
by: Ana Sandoval‐Rodriguez, et al.
Published: (2020-03-01)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2021-06-01)

Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models
by: Marina Galicia-Moreno, et al.
Published: (2021-01-01)

Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects
by: Marina Galicia-Moreno, et al.
Published: (2020-10-01)

Perils with Pirfenidone and “the tuberculosis link”
by: Madhav H Hande, et al.
Published: (2019-01-01)

Antifibrotic activities of pirfenidone in animal models
by: L. Pan, et al.
Published: (2011-06-01)

Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients
by: Simón A. Ojeda-Duran, et al.
Published: (2020-05-01)

Pirfenidone Accelerates Wound Healing in Chronic Diabetic Foot Ulcers: A Randomized, Double-Blind Controlled Trial
by: Luz E. Gasca-Lozano, et al.
Published: (2017-01-01)

Effect of Prolonged-Release Pirfenidone on Renal Function in Septic Acute Kidney Injury Patients: A Double-Blind Placebo-Controlled Clinical Trial
by: Jonathan S. Chávez-Iñiguez, et al.
Published: (2021-01-01)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
by: Takeda Y, et al.
Published: (2014-03-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Application of Pirfenidone anti-fibrosis in ophthalmology
by: Xiao Yang, et al.
Published: (2013-08-01)

Is pirfenidone effective for idiopathic pulmonary fibrosis?
by: Alejandro Jeldres, et al.
Published: (2017-03-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)

Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2021-03-01)

Pirfenidone prevents acute kidney injury in the rat
by: Ixchel Lima-Posada, et al.
Published: (2019-05-01)

Activation of Myofibroblast TRPA1 by Steroids and Pirfenidone Ameliorates Fibrosis in Experimental Crohn's Disease
by: Lin Hai Kurahara, et al.
Published: (2018-01-01)

Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability
by: Marina Campos-Valdez, et al.
Published: (2021-06-01)

Pirfenidone in idiopathic pulmonary fibrosis: Is there a role?
by: I. Galal
Published: (2014-10-01)

Clinical decisions in Hepatology: The pirfenidone case analysis
by: Norberte C. Chavez-Tapia, M.D., et al.
Published: (2014-03-01)

PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
by: Hugo Christian Monroy-Ramirez, et al.
Published: (2021-08-01)

Could Pirfenidone Also be Effective in Treating Intestinal Fibrosis?
by: Giovanni Latella, et al.
Published: (2020-07-01)

Effect of pirfenidone on wound healing in lung transplant patients
by: Amber Mortensen, et al.
Published: (2018-06-01)

The effects of pirfenidone on T helper cells in prevention of intraperitoneal adhesions
by: Kemal Ozbilgin, et al.
Published: (2017-06-01)

Effect of pirfenidone on the proliferation of rat corneal stromal cells
by: Jun-Jie Chen, et al.
Published: (2015-02-01)

Our Experience with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
by: Berna Akıncı Özyürek, et al.
Published: (2016-04-01)

No effect of pirfenidone treatment in fulminant bleomycin-induced pneumonitis
by: Elisabeth Bendstrup, et al.
Published: (2014-01-01)

Reactivation pulmonary tuberculosis in two patients treated with pirfenidone
by: Mohammad Khan, et al.
Published: (2017-01-01)

Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis
by: Eman Shebl, et al.
Published: (2021-03-01)

Effects of pirfenidone on renal function in patients with interstitial pneumonia
by: Jun Matsumoto, et al.
Published: (2021-01-01)

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis
by: Ulrich Costabel, et al.
Published: (2019-03-01)

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
by: Lisa H. Lancaster, et al.
Published: (2017-12-01)

Genomic medicine in Mexico. Applications of gene therapy for cirrhosis reversion
by: Juan Armendariz-Borunda
Published: (2002-10-01)

Not yet known side effects of pirfenidone in the treatment of idiopathic pulmonary fibrosis?
by: S. Campainha, et al.
Published: (2016-03-01)

The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC
by: Sebastian Marwitz, et al.
Published: (2020-01-01)